WilmerHale Advises Orna Therapeutics in $80M Series A Financing
On February 24, 2021, Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNAs), announced the completion of its $80 million Series A financing. The financing will enable Orna to bring its initial programs to IND enablement, while continuing to advance its robust platform and build the capabilities to support Orna’s mission in its new office and laboratory space located in Cambridge, Massachusetts. The Series A financing was co-led by MPM Capital, Taiho Ventures, and F2 Ventures, with from leading strategic investors: Kite, a Gilead Company, Bristol Myers Squibb, Astellas Venture Management, Novartis Institutes for Biomedical Research, and the PAGS Group.
The WilmerHale team advising Orna was led by Rosemary G. Reilly and included Jonathan Jones, Rebecca Nauta and Korey Cowan.